PBLAPanbela Therapeutics, Inc.

About Panbela Therapeutics, Inc. (PBLA)

Panbela Therapeutics, Inc. (PBLA) is a Biotechnology company headquartered in Waconia, MN, United States whose shares trade over-the-counter on the Pink tier.

Panbela Therapeutics, Inc. ("Panbela" and together with its direct and indirect subsidiaries, "we," "us," "our," and the "Company") is a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. Many tumors require greatly elevated levels of polyamines to support their growth and survival. These agents target the polyamine pathway at complementary junctions, which have been shown to be altered in disease. In particular, our lead assets have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system.

Products and services

Clinical stage Drug Development

PBLA key facts

Ticker symbol

PBLA

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Waconia, MN, United States

Country of incorporation

US

Year of incorporation

2011

Employees

8

Estimated market cap

$1.51M (as of Apr 10, 2025)

Shares outstanding

4,854,857

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Feb 12, 2025)

Panbela Therapeutics, Inc. leadership

• Jennifer Kate Simpson — CEO, President
• Susan Horvath — CFO, Secretary, Treasurer, VP, Fin.
• Tammy Groene — VP, Ops.

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with P